Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 33 of 75 for:    stem cell multiple sclerosis

Expanded Access to Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03822858
Expanded Access Status : Available
First Posted : January 30, 2019
Last Update Posted : September 10, 2019
Sponsor:
Information provided by (Responsible Party):
Tisch Multiple Sclerosis Research Center of New York

Tracking Information
First Submitted Date January 24, 2019
First Posted Date January 30, 2019
Last Update Posted Date September 10, 2019
 
Descriptive Information
Brief Title Expanded Access to Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis
Brief Summary To give expanded access to intrathecal autologous MSC-NP treatment to patients with progressive MS who do not meet the inclusion/exclusion criteria of our Phase II stem cell trial.
Detailed Description Not Provided
Study Type Expanded Access
Expanded Access Type Treatment IND/Protocol
Intervention Drug: Intrathecal MSC-NP injection

Between 5 to 10 million MSC-NPs will be administered intrathecally in each dose.

10 million cells is the maximum dose. Treatment will consist of 3-5 doses spaced 3 months apart.

Publications * Harris VK, Stark J, Vyshkina T, Blackshear L, Joo G, Stefanova V, Sara G, Sadiq SA. Phase I Trial of Intrathecal Mesenchymal Stem Cell-derived Neural Progenitors in Progressive Multiple Sclerosis. EBioMedicine. 2018 Mar;29:23-30. doi: 10.1016/j.ebiom.2018.02.002. Epub 2018 Feb 3.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Expanded Access Status Available
Contacts
Contact: Saud A Sadiq, MD, FAAN 212 265 8070 atahir@tischms.org
Contact: Alifiya Tahir, BDS, MPH 212 265 8070 atahir@tischms.org
Listed Location Countries United States
Removed Location Countries  
 
Administrative Information
NCT Number NCT03822858
Responsible Party Tisch Multiple Sclerosis Research Center of New York
Study Sponsor Tisch Multiple Sclerosis Research Center of New York
Collaborators Not Provided
Investigators
Principal Investigator: Saud A Sadiq, MD, FAAN Tisch MS Research Center of New York
PRS Account Tisch Multiple Sclerosis Research Center of New York
Verification Date September 2019